ExThera Medical
Stockholm
30 articles about ExThera Medical
-
ExThera Medical Receives Certification for Medical Device Single Audit Program (MDSAP) and Recertification for International Organization for Standardization for Medical Devices (ISO 13485)
8/15/2023
ExThera Medical Corporation announces it has received simultaneous certification per Medical Device Single Audit Program (MDSAP) and International Organization for Standardization (ISO 13485) requirements.
-
ExThera Medical in Growth Mode after FDA Approval of Investigational Device Exemption
7/26/2023
ExThera Medical Corporation today announces the addition of Michael DiMeo as Chief Financial Officer.
-
ExThera Medical and Asahi Kasei Medical Enter into Partnership to Expand Reach of Treatment for the Critically Ill
12/21/2021
ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera's Seraph® 100 Microbind® Affinity Blood Filter.
-
Seraph 100 Blood Filter Shows Substantially Improved Survival Rates for COVID-19 Patients
4/27/2021
ExThera Medical announced the release of preliminary clinical study data demonstrating significantly improved survival rates among critically ill COVID-19 patients when treated with the Seraph® 100 Microbind® Affinity Blood Filter compared to contemporaneous controls.
-
Michael Porter of Harvard Business School has Joined the Board of Directors of ExThera Medical Corporation
9/29/2020
Michael Porter, Ph.D., has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company focused on the therapeutic reduction of drug-resistant pathogens and sepsis mediators in whole blood. ExThera’s Seraph ® 100 Microbind ® Affinity Blood Filter (Seraph 100) has a CE Mark in Europe for the treatment of a wide range of bloodstream infections. In the USA Seraph 100 has Em
-
ExThera’s Affinity Blood Filter Is Used to Treat COVID-19 Patients
3/26/2020
Treatment of COVID-19 with ExThera’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has begun in hospitals in Germany and Italy. Seraph 100 treatments of COVID-19 are also expected to begin soon in France and the USA. Seraph 100 is the only ‘hemoperfusion device’ approved for the reduction of pathogens in blood. In recent EU clinical cases improved lung function and rapid reduction of dru
-
ExThera Medical Receives CE Mark Approval for the Seraph® 100 Blood Filter
8/6/2019
“A Promising Treatment for Drug-resistant Bloodstream Infections and Sepsis”
-
ExThera Medical Elects Preston and Dollarhyde to its Board of Directors to Drive the Organization’s Next Phase of Innovation and Growth
1/7/2019
ExThera, an early-stage device company in the Bay Area, is a developer of device-based therapies for removing bacteria and viruses from blood.
-
ExThera Medical Announces Completion of CE Mark Registration Trial Evaluating the Safety of Seraph® 100 Blood Filter
6/11/2018
ExThera Medical Corporation today announced that it completed its CE Mark registration trial evaluating the safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph) in renal replacement therapy patients who developed bacteremia.
-
ExThera Medical Announces Creation of European Subsidiary
3/19/2018
ExThera Medical Corporation announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary.
-
ExThera Medical’s ‘Seraph’ Blood Filter Successfully Completes Pre-Clinical Testing in Final Phase of DARPA’s DLT Program
1/25/2018
ExThera Medica today announced that the safety and effectiveness of its Seraph 200 Microbind Affinity Blood Filter (Seraph 200) has been demonstrated in pre-clinical testing.
-
FDA Grants ExThera Medical’s Seraph 100 Blood Filter Expedited Access Pathway (EAP) Designation
8/30/2017
-
DARPA Funds ExThera Medicall’s "Seraph" Blood Filter For Pre-Clinical Testing
7/10/2017
-
ExThera MedicalCloses Financing Led By Fresenius Medical Care Ventures To Support Commercialization Of Innovative Technology To Remove Pathogens From Whole Blood
6/1/2016
-
ExThera Medical Achieves Promising Preliminary Safety And Efficacy Results In A Large-Animal Model
1/11/2016
-
ExThera Medical Presents Results Of Cytomegalovirus (CMV) Binding Study
1/28/2015
-
ExThera Medical Joins Battelle Team To Work On DARPA’s DLT Program, Aimed At Developing A Medical Device For Treating Sepsis
1/7/2015
-
ExThera Medical Publishes Results Of "CRE Superbug" Binding Study: A Device-Based Therapy For Drug-resistant Bacterial Infections Is Now Possible
12/4/2014
-
ExThera Medical Posts $3.75 Million First Closing Of Its $7 Million Convertible Note Offering
10/6/2014
-
ExThera Medical Appoints John W. Feik To Its Board Of Directors
9/12/2014